393 related articles for article (PubMed ID: 30572736)
1. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
2. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
4. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
6. Investigational MET inhibitors to treat Renal cell carcinoma.
Nandagopal L; Sonpavde GP; Agarwal N
Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
[No Abstract] [Full Text] [Related]
7. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Bhargava P; Robinson MO
Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
11. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
[TBL] [Abstract][Full Text] [Related]
12. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson TE
Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
17. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
19. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
